Resource Center
Resource Center
As part of a growing portfolio of biomedical HIV prevention options, long-acting injectable cabotegravir (CAB-LA) was approved by the US FDA in December 2021. Evidence from two clinical trials, HPTN 083 and HPTN 084, which enrolled nearly 8,000 participants across 13 countries (including 7 countries in sub-Saharan Africa), demonstrated that CAB-LA is safe and highly...
Read more
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI.
Read more
New test-and-treat consortium to quickly provide Ministries of Health in 10 low- and middle-income countries with oral antiviral treatments to high-risk patients and scale up wider access through 2023.
Read more
A critical second-line HIV treatment called darunavir/ritonavir (DRV/r) is rolling out across Nigeria and Zambia – some of the earliest adopters of many countries that can now access an affordable supply of these medicines following a pricing agreement secured by CHAI and Unitaid last year.
Read more
With CHAI support, Nasarawa State in Nigeria has rolled out integrated hepatitis C and HIV testing.
Read more
The Clinton Health Access Initiative (CHAI) has received US$25 million in new funding commitments from the Bill & Melinda Gates Foundation and The ELMA Foundation to help nine governments build comprehensive oxygen ecosystems.
Read more
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI.
Read more
Global AIDS fight ‘in danger’ but there is still time to get back on track, participants hear at AIDS 2022 conference. A few short weeks ago, CHAI marked the start of our 20th anniversary. We remembered the 2002 AIDS conference in Barcelona, which helped launch our organization, and the barriers to treatment people living with HIV faced...
Read more
As Nigeria prepares to roll out the HIV/syphilis dual test, health workers share why it is so critical for pregnant women.
Read more
MedAccess, Unitaid, The Aurum Institute, and the Clinton Health Access Initiative (CHAI) have announced two new agreements to lower the price of rifapentine-based treatments to prevent tuberculosis in low- and middle-income countries.
Read more